医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Gemtech Targets the Asian Market with Its Medical Devices and Coating and Plating, and Special Spray Products

2019年07月16日 AM10:00
このエントリーをはてなブックマークに追加


 

CHANGWON, South Korea

Gemtech Co., Ltd. is enhancing its R&D and marketing capability to expand the business into the Asian market with its medical devices, coating and plating facility, and special spray products.

Gemtech is focused on designing and manufacturing high-quality products from medical devices including low-frequency therapeutic units, therapeutic ultrasound units, phototherapy units, and devices for rehabilitation; electrophoretic, particulate, and shot coating facilities; to ceramic, lubricating, and Teflon coating systems.

Gemtech’s flagship products include Tea Tree 10 Spotcare made of tea tree oil, cotton swab lip tint and remover, GT-K100 massage machine for gonarthritis, small-sized low-frequency stimulator PULSE EGG SR-50, TENS menstrual pain reliever, and high-frequency thermography unit SIRIUS.

Founded in January 1996, Gemtech established its own research institute and selected as one of the promising small and medium enterprises. Under the management philosophy of “we produce the best quality products, keeping in mind that our family members use the product we produced,” the company is focused on achieving goals including 100 percent customer approval rating, zero defection, building the best quality assurance system, and globalizing its brand. Approved by FDA and certified according to ISO 14001, the company’s various products are known for excellent technology and exported to Japan. Currently, Gemtech is committed to expanding its business into the global market.

Gemtech Technology Institute is accelerating its R&D to boost human health by improving the quality of life through new technology and products in the medical device industry.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190715005840/en/

CONTACT

Gemtech Co., Ltd.

Cho Hong Sig

+82-55-237-5533

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 米国FDAが武田薬品のタクザイロ®(ラナデルマブ・フライオ)を2歳以上の小児における遺伝性血管性浮腫(HAE)発作の予防薬として承認
  • Award-Winning Data CRO Expands Executive Leadership to Support Company’s Next Stage of Growth
  • Avania Acquires MAXIS, Advancing MedTech Leadership in Pre-Clinical, Regulatory Strategy, and Clinical Expertise
  • Corentec Appoints Michael Son as Executive Vice President
  • Emids Names Sean Narayanan as Chief Executive Officer with Founder Saurabh Sinha to Become Chairman